This work was performed in the Departments of Urology and Pathology at the Johns Hopkins University School of Medicine and in the Department of Urology and the Comprehensive Cancer Center at the University of Michigan Medical School.
Article first published online: 21 JUN 2012
Copyright © 2012 Wiley Periodicals, Inc.
Volume 73, Issue 2, pages 176–181, January 2013
How to Cite
Jones, M. L., Siddiqui, J., Pienta, K. J. and Getzenberg, R. H. (2013), Circulating fibroblast-like cells in men with metastatic prostate cancer. Prostate, 73: 176–181. doi: 10.1002/pros.22553
The authors have no conflicts of interest to disclose.
- Issue published online: 24 DEC 2012
- Article first published online: 21 JUN 2012
- Manuscript Accepted: 29 MAY 2012
- Manuscript Received: 26 JAN 2012
- Patana Fund of the Brady Urological Institute
- National Cancer Institute Prostate Cancer SPORE. Grant Numbers: P50 CA58236, P50 CA69568
Metastatic prostate cancer is an incurable disease. During the development of this disease, prostate cancer cells enter the bloodstream as single cells or clusters of cells. Prostate fibroblasts, a cancer-promoting cell type in the prostate cancer microenvironment, could in theory incorporate into these migrating cell clusters or follow cancer cells into the bloodstream through holes in the tumor vasculature. Based on this idea, we hypothesized that fibroblast-like cells, defined here as cytokeratin 8/18/19−/DAPI+/CD45−/vimentin+ cells, are present in the blood of men with metastatic prostate cancer.
Veridex's CellSearch® system was used to immunomagnetically capture EpCAM+ cells and clusters of cells heterogeneous for EpCAM expression from the blood of men with metastatic prostate cancer, localized cancer, and no known cancer, and immunostain them for the presence of cytokeratins 8/18/19, a nucleus, CD45, and vimentin. Fibroblast-like cells were then quantified.
Fibroblast-like cells were present in 58.3% of men with metastatic prostate cancer but not in any men with localized prostate cancer or no known cancer. The presence of these cells correlated with certain known indicators of poor prognosis: ≥5 circulating tumor cells, defined here as cytokeratin 8/18/19+/DAPI+/CD45− cells, per 7.5 ml of blood, and a relatively high serum prostate-specific antigen level of ≥20 ng/ml.
The presence of fibroblast-like cells in the blood may provide prognostic information as well as information about the biology of metastatic prostate cancer. Prostate 73: 176–181, 2013. © 2012 Wiley Periodicals, Inc.